News
12-10-2010, 10:10 AM
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone...
More... (http://mnt.to/f/3NT5)
More... (http://mnt.to/f/3NT5)